In REDEFINE 2, which included participants with type 2 diabetes (a population that typically shows lower weight loss with any intervention), CagriSema achieved 13.7% weight loss compared to 3.4% with placebo
At InjectCo, our goal is to provide incredible support and comprehensive treatment as part of a sustainable weight loss program without you having to worry too much about spending or cost
Ethics declarations Competing interests Through M.H.H.K., the VU University Medical Center has received research grants from AstraZeneca, Boehringer Ingelheim, Novo Nordisk and Sanofi
For the 9 mg target, doses increased in steps at 2 mg, 4 mg, and 6 mg, with increases every four weeks until reaching 9 mg
Assumptions used in the base case analysis were based on observations from other long-term studies and were tested in sensitivity analyses